Myovant Sciences Ltd

NYSE:MYOV   3:59:59 PM EDT
21.14
-0.14 (-0.66%)
4:13:22 PM EDT: $21.43 +0.29 (+1.37%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.92B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.2 Million
Adjusted EPS-$0.87
See more estimates
10-Day MA$22.18
50-Day MA$22.49
200-Day MA$17.71
See more pivots

Myovant Sciences Ltd. Stock, NYSE:MYOV

20-22 BEDFORD ROW, LONDON, UNITED KINGDOM WC1R 4JS
Bermuda
Phone: (441) 824-8101
Number of Employees: 20

Description

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. was founded in 2016 and is based in Hamilton, Bermuda. Myovant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd.